Fareed Kow Nanse Arthur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fareed Kow Nanse Arthur has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
- Lord Jephthah Joojo Gowans
Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana
8 shared publications - Adebowale Adeyemo
Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
7 shared publications - Azeez Butali
Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, USA
7 shared publications - Solomon Obiri-Yeboah
School of Dentistry, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
6 shared publications James Olutayo
Oral and Maxillofacial Surgery University of Lagos Idiaraba
3 shared publications- Lawrence Owusu
Department of Medical Biochemistry and Molecular Biology, Dalian Medical University, 9 Western Section, Lvshun South Street Lvshunkou District 116044, Dalian City, PR China
3 shared publications
Latest Publications
- Open Access
- 22 October 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 875
Pathogenic FANCC Variants Are Associated with Accessory Breasts in a Sub-Saharan African Multiplex Family
Accessory breasts denote the formation of extra breast tissue along the milk line, and are known to be more prevalent among Black and Asian populations, affecting both genders. This first-ever study aimed to determine the genetic aetiology of accessory breasts in a multiplex family, where all female siblings present with bilateral accessory breasts. The study also ascertained secondary findings (SFs) responsible for comorbidities. Clinical data and saliva samples were obtained from all family members. Ultrasound and histopathology confirmed the diagnosis. Whole-exome sequencing was conducted on DNA samples obtained from the saliva, with variant calling conducted utilising the Sentieon workflow. Variant classification was based on American College of Medical Genetics and Genomics guidelines. After segregation analysis, 12 candidate genes emerged. Among these, PRSS50 and FANCC emerged as top candidates, being implicated in breast diseases. However, two variants in FANCC (c.360del; p.His120GlnfsTer24 and c.355_358del; p.Ser119IlefsTer24) were selected as the most probable causal variants because of the role of this gene in hereditary breast and ovarian cancer syndromes. The remaining ten genes were reported as potentially accounting for comorbidities segregating with accessory breasts. Reported SFs involve TTR and RYR1. In conclusion, pathogenic variants in FANCC cause familial accessory breasts. These novel observations impact pathophysiology, genetic counselling, and personalised medicine.
- 22 October 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (11) , 875
Open AccessPathogenic FANCC Variants Are Associated with Accessory Breasts in a Sub-Saharan African Multiplex Family
Accessory breasts denote the formation of extra breast tissue along the milk line, and are known to be more prevalent among Black and Asian populations, affecting both genders. This first-ever study aimed to determine the genetic aetiology of accessory breasts in a multiplex family, where all female siblings present with bilateral accessory breasts. The study also ascertained secondary findings (SFs) responsible for comorbidities. Clinical data and saliva samples were obtained from all family members. Ultrasound and histopathology confirmed the diagnosis. Whole-exome sequencing was conducted on DNA samples obtained from the saliva, with variant calling conducted utilising the Sentieon workflow. Variant classification was based on American College of Medical Genetics and Genomics guidelines. After segregation analysis, 12 candidate genes emerged. Among these, PRSS50 and FANCC emerged as top candidates, being implicated in breast diseases. However, two variants in FANCC (c.360del; p.His120GlnfsTer24 and c.355_358del; p.Ser119IlefsTer24) were selected as the most probable causal variants because of the role of this gene in hereditary breast and ovarian cancer syndromes. The remaining ten genes were reported as potentially accounting for comorbidities segregating with accessory breasts. Reported SFs involve TTR and RYR1. In conclusion, pathogenic variants in FANCC cause familial accessory breasts. These novel observations impact pathophysiology, genetic counselling, and personalised medicine.
- Open Access
- 29 September 2025
- Published by MDPI AG in Preprints.org
Pathogenic FANCC Variants are Associated with Accessory Breasts in a Sub-Saharan African Multiplex Family
Accessory breasts denote the formation of extra breast tissue along the milk line, being more prevalent among Black and Asian populations, affecting both genders. This study aimed to determine the genetic aetiology of accessory breasts in a multiplex family, where all female siblings presented with bilateral accessory breasts. The study also ascertained secondary findings (SFs) that may impact the health of the family members. Clinical data and saliva samples were obtained from all family members. Ultrasound and histopathology confirmed the diagnosis. Whole-exome sequencing was conducted on DNA samples obtained from the saliva, with variant calling conducted utilizing Sentieon workflow. Variant classification was based on American College of Medical Genetics and Genomics guidelines. After segregation analysis, 12 candidate genes emerged. Among these, PRSS50 and FANCC emerged as top candidates, being implicated in breast diseases. However, two variants in FANCC (c.360del; p.His120GlnfsTer24 and c.355_358del; p.Ser119IlefsTer24) were selected as the most probable causal variants because of the role of this gene in familial hereditary breast and ovarian cancer syndromes. The remaining ten genes were reported as potentially accounting for co-occurring conditions segregating with accessory breasts. Reported SFs involve TTR and RYR1. In conclusion, pathogenic variants in FANCC are causal for familial accessory breasts.
- 29 September 2025
- Published by MDPI AG in Preprints.org
Open AccessPathogenic FANCC Variants are Associated with Accessory Breasts in a Sub-Saharan African Multiplex Family
Accessory breasts denote the formation of extra breast tissue along the milk line, being more prevalent among Black and Asian populations, affecting both genders. This study aimed to determine the genetic aetiology of accessory breasts in a multiplex family, where all female siblings presented with bilateral accessory breasts. The study also ascertained secondary findings (SFs) that may impact the health of the family members. Clinical data and saliva samples were obtained from all family members. Ultrasound and histopathology confirmed the diagnosis. Whole-exome sequencing was conducted on DNA samples obtained from the saliva, with variant calling conducted utilizing Sentieon workflow. Variant classification was based on American College of Medical Genetics and Genomics guidelines. After segregation analysis, 12 candidate genes emerged. Among these, PRSS50 and FANCC emerged as top candidates, being implicated in breast diseases. However, two variants in FANCC (c.360del; p.His120GlnfsTer24 and c.355_358del; p.Ser119IlefsTer24) were selected as the most probable causal variants because of the role of this gene in familial hereditary breast and ovarian cancer syndromes. The remaining ten genes were reported as potentially accounting for co-occurring conditions segregating with accessory breasts. Reported SFs involve TTR and RYR1. In conclusion, pathogenic variants in FANCC are causal for familial accessory breasts.
- Open Access
- 14 July 2021
- Published by IntechOpen
IL-17 Biological Effects and Signaling Mechanisms in Human Leukemia U937 Cells
Human Interlekin-17 is produced by memory activated CD4+ T cells and other cells. It was initially considered unique in that its specific receptor is distinct from other cytokine receptors. IL-17 receptor is ubiquitously expressed by different cells including T cells. IL-17 plays a role in regulating growth, immune response and pro-inflammatory responses. It regulates differentiation of a subset of Th0 cells into Th-17 cells, which produce IL-17-induced cytokines. The IL-17R belongs to type 1 cytokine receptors. IL-17 belongs to a superfamily of its own, which includes IL-17A, IL-17B, IL-17C, IL-17E and IL-17F. These members of IL-17 superfamily have some sequence homology but bind to different receptors. Prior to this investigation, limited information existed on the effects of IL-17A in human leukemia cell lines. Our results show that IL-17A promotes growth, anti-apoptotic effects, chemotaxis, cytokine expression and transcriptional factor activation in leukemia cells. IL-17A activates multiple signaling pathways including PI-3 K, Jak–STAT, Raf-ERK1/2 and SRC kinase pathways, which mediate different biological effects of IL-17A in leukemia cells. Our findings implicate IL-17A in leukemia cell growth and survival, supporting potential leukemia therapy via development of anti-IL-17A drugs. This chapter focuses on IL-17A, herein referred to as IL-17.
- 14 July 2021
- Published by IntechOpen
Open AccessIL-17 Biological Effects and Signaling Mechanisms in Human Leukemia U937 Cells
Human Interlekin-17 is produced by memory activated CD4+ T cells and other cells. It was initially considered unique in that its specific receptor is distinct from other cytokine receptors. IL-17 receptor is ubiquitously expressed by different cells including T cells. IL-17 plays a role in regulating growth, immune response and pro-inflammatory responses. It regulates differentiation of a subset of Th0 cells into Th-17 cells, which produce IL-17-induced cytokines. The IL-17R belongs to type 1 cytokine receptors. IL-17 belongs to a superfamily of its own, which includes IL-17A, IL-17B, IL-17C, IL-17E and IL-17F. These members of IL-17 superfamily have some sequence homology but bind to different receptors. Prior to this investigation, limited information existed on the effects of IL-17A in human leukemia cell lines. Our results show that IL-17A promotes growth, anti-apoptotic effects, chemotaxis, cytokine expression and transcriptional factor activation in leukemia cells. IL-17A activates multiple signaling pathways including PI-3 K, Jak–STAT, Raf-ERK1/2 and SRC kinase pathways, which mediate different biological effects of IL-17A in leukemia cells. Our findings implicate IL-17A in leukemia cell growth and survival, supporting potential leukemia therapy via development of anti-IL-17A drugs. This chapter focuses on IL-17A, herein referred to as IL-17.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Variant Analyses of Candidate Genes in Orofacial Clefts in Multi‐Ethnic Populations
Cleft lip with or without cleft palate (CL/P) and cleft palate only (CPO) are congenital birth defects where the upper lip and/or palate fail to fuse properly during embryonic facial development. CL/P and CPO fall under the larger category of orofacial clefts (OFCs), which affect ~1.2/1000 live births world‐wide and imposes significant social and financial burdens on affected individuals and their families. The etiology of orofacial clefts is complex and likely results from a combination of genetic mutations with environmental covariates. Recent genome wide association studies (GWAS) and whole exome sequencing (WES) for orofacial clefting identified significant genetic associations and variants in several genes. Of these genes, we investigated the role of common and rare variants in the SHH , RORA , MRPL53 , ACVR1 , and GDF11 genes. We sequenced these five genes in multi‐ethnic CL/P and CPO samples in order to find mutations that may provide potential explanations for OFCs missing heritability. In total, 19 variants of interest were found, seven of which were in SHH , one in RORA , three in MRPL53 , six in ACVR1 , and two in GDF11 . Types of mutations found included stop‐gained, missense, synonymous, intronic, and splice site variants. Of these 19 variants, 3 novel missense variants were found, one in SHH , one in RORA , and one in GDF11 . Rare and novel variants were further analyzed using in‐silico predictive tools such as SIFT, Polyphen‐2, Provean score, CADD, and HOPE. This study provides evidence that mutations in SHH , RORA , MRPL53 , ACVR1 , and GDF11 may contribute to risk of OFCs in various populations.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessVariant Analyses of Candidate Genes in Orofacial Clefts in Multi‐Ethnic Populations
Cleft lip with or without cleft palate (CL/P) and cleft palate only (CPO) are congenital birth defects where the upper lip and/or palate fail to fuse properly during embryonic facial development. CL/P and CPO fall under the larger category of orofacial clefts (OFCs), which affect ~1.2/1000 live births world‐wide and imposes significant social and financial burdens on affected individuals and their families. The etiology of orofacial clefts is complex and likely results from a combination of genetic mutations with environmental covariates. Recent genome wide association studies (GWAS) and whole exome sequencing (WES) for orofacial clefting identified significant genetic associations and variants in several genes. Of these genes, we investigated the role of common and rare variants in the SHH , RORA , MRPL53 , ACVR1 , and GDF11 genes. We sequenced these five genes in multi‐ethnic CL/P and CPO samples in order to find mutations that may provide potential explanations for OFCs missing heritability. In total, 19 variants of interest were found, seven of which were in SHH , one in RORA , three in MRPL53 , six in ACVR1 , and two in GDF11 . Types of mutations found included stop‐gained, missense, synonymous, intronic, and splice site variants. Of these 19 variants, 3 novel missense variants were found, one in SHH , one in RORA , and one in GDF11 . Rare and novel variants were further analyzed using in‐silico predictive tools such as SIFT, Polyphen‐2, Provean score, CADD, and HOPE. This study provides evidence that mutations in SHH , RORA , MRPL53 , ACVR1 , and GDF11 may contribute to risk of OFCs in various populations.
- Open Access
- 17 June 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (8) , e1355
Non‐random distribution of deleterious mutations in the DNA and protein‐binding domains of IRF6 are associated with Van Der Woude syndrome
Background: The development of the face occurs during the early days of intrauterine life by the formation of facial processes from the first Pharyngeal arch. Derangement in these well‐organized fusion events results in Orofacial clefts (OFC). Van der Woude syndrome (VWS) is one of the most common causes of syndromic cleft lip and/or palate accounting for 2% of all cases. Mutations in the IRF6 gene account for 70% of cases with the majority of these mutations located in the DNA‐binding (exon 3, 4) or protein‐binding domains (exon 7–9). The current study was designed to update the list of IRF6 variants reported for VWS by compiling all the published mutations from 2013 to date as well as including the previously unreported VWS cases from Africa and Puerto Rico.Methods: We used PubMed with the search terms; "Van der Woude syndrome," “Popliteal pterygium syndrome,” "IRF6," and "Orofacial cleft" to identify eligible studies. We compiled the CADD score for all the mutations to determine the percentage of deleterious variants.Results: Twenty‐one new mutations were identified from nine papers. The majority of these mutations were in exon 4. Mutations in exon 3 and 4 had CADD scores between 20 and 30 and mutations in exon 7–9 had CADD scores between 30 and 40. The presence of higher CADD scores in the protein‐binding domain (exon 7–9) further confirms the crucial role played by this domain in the function of IRF6. In the new cases, we identified five IRF6 mutations, three novel missense mutations (p.Phe36Tyr, p.Lys109Thr, and p.Gln438Leu), and two previously reported nonsense mutations (p.Ser424*and p.Arg250*).Conclusion: Mutations in the protein and DNA‐binding domains of IRF6 ranked among the top 0.1% and 1% most deleterious genetic mutations, respectively. Overall, these findings expand the range of VWS mutations and are important for diagnostic and counseling purposes.
- 17 June 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (8) , e1355
Open AccessNon‐random distribution of deleterious mutations in the DNA and protein‐binding domains of IRF6 are associated with Van Der Woude syndrome
Background: The development of the face occurs during the early days of intrauterine life by the formation of facial processes from the first Pharyngeal arch. Derangement in these well‐organized fusion events results in Orofacial clefts (OFC). Van der Woude syndrome (VWS) is one of the most common causes of syndromic cleft lip and/or palate accounting for 2% of all cases. Mutations in the IRF6 gene account for 70% of cases with the majority of these mutations located in the DNA‐binding (exon 3, 4) or protein‐binding domains (exon 7–9). The current study was designed to update the list of IRF6 variants reported for VWS by compiling all the published mutations from 2013 to date as well as including the previously unreported VWS cases from Africa and Puerto Rico.Methods: We used PubMed with the search terms; "Van der Woude syndrome," “Popliteal pterygium syndrome,” "IRF6," and "Orofacial cleft" to identify eligible studies. We compiled the CADD score for all the mutations to determine the percentage of deleterious variants.Results: Twenty‐one new mutations were identified from nine papers. The majority of these mutations were in exon 4. Mutations in exon 3 and 4 had CADD scores between 20 and 30 and mutations in exon 7–9 had CADD scores between 30 and 40. The presence of higher CADD scores in the protein‐binding domain (exon 7–9) further confirms the crucial role played by this domain in the function of IRF6. In the new cases, we identified five IRF6 mutations, three novel missense mutations (p.Phe36Tyr, p.Lys109Thr, and p.Gln438Leu), and two previously reported nonsense mutations (p.Ser424*and p.Arg250*).Conclusion: Mutations in the protein and DNA‐binding domains of IRF6 ranked among the top 0.1% and 1% most deleterious genetic mutations, respectively. Overall, these findings expand the range of VWS mutations and are important for diagnostic and counseling purposes.
- Open Access
- 19 June 2019
- Published by Oxford University Press (OUP) in Translational Animal Science
- Vol. 3 (4) , 1112-1118
Feeding differing direct-fed microbials and its influence on growth and haematological parameters of growing lambs1
A 4 mo feeding trial was conducted to ascertain the effect of direct-fed microbial (DFM) and their products, namely rumen enhancer three (RE3), Paenibacillus polymyxa (P3), and a fermentation product of RE3—RE3 Plus on the growth and haematological profile of lambs at different stages of growth (suckling, weaner, and grower phases). The lambs weighing 2.5 ± 2 kg were blocked by their weights and allotted to four dietary treatments, namely Control, RE3, RE3 Plus, and P3 in a randomized complete block design. Blood sampling of lambs to investigate the effect of the treatments on the haematological and blood biochemistry variables was done on monthly basis and analysis of variance in a repeated measures design was done using the Statistical Analysis System. Feed intake (FI) by lambs was not significantly (P > 0.05) influenced by DFM supplementation for all the phases of growth. However, feed conversion ratio (FCR) for the grower phase of the lamb was higher for T2. Similar (P > 0.05) hemoglobin (Hb), red blood cell (RBC), pack cell volume (PCV), mean corpuscular volume, mean corpuscular hemoglobin concentration (MCHC), eosinophil, lymphocyte, and basophil composition were recorded for lambs on the different experimental diets. Neutrophil and monocytes levels were, however, different (P < 0.05) for lambs fed the varying dietary treatments with lambs on RE3 Plus diets recording the lowest (P < 0.05) neutrophil levels. Monocytes levels were highest (P < 0.05) in lambs fed diets fortified with RE3. Sampling period influenced (P < 0.05) the Hb, RBC, PCV, MCHC, eosinophil, monocyte, and lymphocyte levels. The trial revealed a significant treatment × sampling period interaction (P < 0.0001) for the blood parameters examined. The inclusion of the different DFM products had no influence on the growth characteristics and blood profile of growing lambs.
- 19 June 2019
- Published by Oxford University Press (OUP) in Translational Animal Science
- Vol. 3 (4) , 1112-1118
Open AccessFeeding differing direct-fed microbials and its influence on growth and haematological parameters of growing lambs1
A 4 mo feeding trial was conducted to ascertain the effect of direct-fed microbial (DFM) and their products, namely rumen enhancer three (RE3), Paenibacillus polymyxa (P3), and a fermentation product of RE3—RE3 Plus on the growth and haematological profile of lambs at different stages of growth (suckling, weaner, and grower phases). The lambs weighing 2.5 ± 2 kg were blocked by their weights and allotted to four dietary treatments, namely Control, RE3, RE3 Plus, and P3 in a randomized complete block design. Blood sampling of lambs to investigate the effect of the treatments on the haematological and blood biochemistry variables was done on monthly basis and analysis of variance in a repeated measures design was done using the Statistical Analysis System. Feed intake (FI) by lambs was not significantly (P > 0.05) influenced by DFM supplementation for all the phases of growth. However, feed conversion ratio (FCR) for the grower phase of the lamb was higher for T2. Similar (P > 0.05) hemoglobin (Hb), red blood cell (RBC), pack cell volume (PCV), mean corpuscular volume, mean corpuscular hemoglobin concentration (MCHC), eosinophil, lymphocyte, and basophil composition were recorded for lambs on the different experimental diets. Neutrophil and monocytes levels were, however, different (P < 0.05) for lambs fed the varying dietary treatments with lambs on RE3 Plus diets recording the lowest (P < 0.05) neutrophil levels. Monocytes levels were highest (P < 0.05) in lambs fed diets fortified with RE3. Sampling period influenced (P < 0.05) the Hb, RBC, PCV, MCHC, eosinophil, monocyte, and lymphocyte levels. The trial revealed a significant treatment × sampling period interaction (P < 0.0001) for the blood parameters examined. The inclusion of the different DFM products had no influence on the growth characteristics and blood profile of growing lambs.
- Open Access
- 19 November 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 28 (6) , 1038-1051
Genomic analyses in African populations identify novel risk loci for cleft palate
Orofacial clefts are common developmental disorders that pose significant clinical, economical and psychological problems. We conducted genome-wide association analyses for cleft palate only (CPO) and cleft lip with or without palate (CL/P) with ~17 million markers in sub-Saharan Africans. After replication and combined analyses, we identified novel loci for CPO at or near genome-wide significance on chromosomes 2 (near CTNNA2) and 19 (near SULT2A1). In situ hybridization of Sult2a1 in mice showed expression of SULT2A1 in mesenchymal cells in palate, palatal rugae and palatal epithelium in the fused palate. The previously reported 8q24 was the most significant locus for CL/P in our study, and we replicated several previously reported loci including PAX7 and VAX1.
- 19 November 2018
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 28 (6) , 1038-1051
Open AccessGenomic analyses in African populations identify novel risk loci for cleft palate
Orofacial clefts are common developmental disorders that pose significant clinical, economical and psychological problems. We conducted genome-wide association analyses for cleft palate only (CPO) and cleft lip with or without palate (CL/P) with ~17 million markers in sub-Saharan Africans. After replication and combined analyses, we identified novel loci for CPO at or near genome-wide significance on chromosomes 2 (near CTNNA2) and 19 (near SULT2A1). In situ hybridization of Sult2a1 in mice showed expression of SULT2A1 in mesenchymal cells in palate, palatal rugae and palatal epithelium in the fused palate. The previously reported 8q24 was the most significant locus for CL/P in our study, and we replicated several previously reported loci including PAX7 and VAX1.
- Open Access
- 8 September 2017
- Published by SAGE Publications in Journal of Dental Research
- Vol. 97 (1) , 41-48
Loss-of-Function GRHL3 Variants Detected in African Patients with Isolated Cleft Palate
In contrast to the progress that has been made toward understanding the genetic etiology of cleft lip with or without cleft palate, relatively little is known about the genetic etiology for cleft palate only (CPO). A common coding variant of grainyhead like transcription factor 3 (GRHL3) was recently shown to be associated with risk for CPO in Europeans. Mutations in this gene were also reported in families with Van der Woude syndrome. To identify rare mutations in GRHL3 that might explain the missing heritability for CPO, we sequenced GRHL3 in cases of CPO from Africa. We recruited participants from Ghana, Ethiopia, and Nigeria. This cohort included case-parent trios, cases and other family members, as well as controls. We sequenced exons of this gene in DNA from a total of 134 nonsyndromic cases. When possible, we sequenced them in parents to identify de novo mutations. Five novel mutations were identified: 2 missense (c.497C>A; p.Pro166His and c.1229A>G; p.Asp410Gly), 1 splice site (c.1282A>C p.Ser428Arg), 1 frameshift (c.470delC; p.Gly158Alafster55), and 1 nonsense (c.1677C>A; p.Tyr559Ter). These mutations were absent from 270 sequenced controls and from all public exome and whole genome databases, including the 1000 Genomes database (which includes data from Africa). However, 4 of the 5 mutations were present in unaffected mothers, indicating that their penetrance is incomplete. Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site. Overexpression assays in zebrafish and reporter assays in vitro indicated that 4 variants were functionally null or hypomorphic, while 1 was dominant negative. This study provides evidence that, as in Caucasian populations, mutations in GRHL3 contribute to the risk of nonsyndromic CPO in the African population.
- 8 September 2017
- Published by SAGE Publications in Journal of Dental Research
- Vol. 97 (1) , 41-48
Open AccessLoss-of-Function GRHL3 Variants Detected in African Patients with Isolated Cleft Palate
In contrast to the progress that has been made toward understanding the genetic etiology of cleft lip with or without cleft palate, relatively little is known about the genetic etiology for cleft palate only (CPO). A common coding variant of grainyhead like transcription factor 3 (GRHL3) was recently shown to be associated with risk for CPO in Europeans. Mutations in this gene were also reported in families with Van der Woude syndrome. To identify rare mutations in GRHL3 that might explain the missing heritability for CPO, we sequenced GRHL3 in cases of CPO from Africa. We recruited participants from Ghana, Ethiopia, and Nigeria. This cohort included case-parent trios, cases and other family members, as well as controls. We sequenced exons of this gene in DNA from a total of 134 nonsyndromic cases. When possible, we sequenced them in parents to identify de novo mutations. Five novel mutations were identified: 2 missense (c.497C>A; p.Pro166His and c.1229A>G; p.Asp410Gly), 1 splice site (c.1282A>C p.Ser428Arg), 1 frameshift (c.470delC; p.Gly158Alafster55), and 1 nonsense (c.1677C>A; p.Tyr559Ter). These mutations were absent from 270 sequenced controls and from all public exome and whole genome databases, including the 1000 Genomes database (which includes data from Africa). However, 4 of the 5 mutations were present in unaffected mothers, indicating that their penetrance is incomplete. Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site. Overexpression assays in zebrafish and reporter assays in vitro indicated that 4 variants were functionally null or hypomorphic, while 1 was dominant negative. This study provides evidence that, as in Caucasian populations, mutations in GRHL3 contribute to the risk of nonsyndromic CPO in the African population.
- Open Access
- 12 January 2017
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 5 (2) , 164-171
The prevalence, penetrance, and expressivity of etiologicIRF6variants in orofacial clefts patients from sub‐Saharan Africa
Background: Orofacial clefts are congenital malformations of the orofacial region, with a global incidence of one per 700 live births. Interferon Regulatory Factor 6 (IRF6) (OMIM:607199) gene has been associated with the etiology of both syndromic and nonsyndromic orofacial clefts. The aim of this study was to show evidence of potentially pathogenic variants inIRF6in orofacial clefts cohorts from Africa.Methods: We carried out Sanger Sequencing onDNAfrom 184 patients with nonsyndromic orofacial clefts and 80 individuals with multiple congenital anomalies that presented with orofacial clefts. We sequenced all the nine exons ofIRF6as well as the 5′ and 3′ untranslated regions. In our analyses pipeline, we used various bioinformatics tools to detect and describe the potentially etiologic variants.Results: We observed that potentially etiologic exonic and splice site variants were nonrandomly distributed among the nine exons ofIRF6, with 92% of these variants occurring in exons 4 and 7. Novel variants were also observed in both nonsyndromic orofacial clefts (p.Glu69Lys, p.Asn185Thr, c.175‐2A>C and c.1060+26C>T) and multiple congenital anomalies (p.Gly65Val, p.Lys320Asn and c.379+1G>T) patients. Our data also show evidence of compound heterozygotes that may modify phenotypes that emanate fromIRF6variants.Conclusions: This study demonstrates that exons 4 and 7 ofIRF6are mutational ‘hotspots’ in our cohort and thatIRF6mutants‐induced orofacial clefts may be prevalent in the Africa population, however, with variable penetrance and expressivity. These observations are relevant for detection of high‐risk families as well as genetic counseling. In conclusion, we have shown that there may be a need to combine both molecular and clinical evidence in the grouping of orofacial clefts into syndromic and nonsyndromic forms.
- 12 January 2017
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 5 (2) , 164-171
Open AccessThe prevalence, penetrance, and expressivity of etiologicIRF6variants in orofacial clefts patients from sub‐Saharan Africa
Background: Orofacial clefts are congenital malformations of the orofacial region, with a global incidence of one per 700 live births. Interferon Regulatory Factor 6 (IRF6) (OMIM:607199) gene has been associated with the etiology of both syndromic and nonsyndromic orofacial clefts. The aim of this study was to show evidence of potentially pathogenic variants inIRF6in orofacial clefts cohorts from Africa.Methods: We carried out Sanger Sequencing onDNAfrom 184 patients with nonsyndromic orofacial clefts and 80 individuals with multiple congenital anomalies that presented with orofacial clefts. We sequenced all the nine exons ofIRF6as well as the 5′ and 3′ untranslated regions. In our analyses pipeline, we used various bioinformatics tools to detect and describe the potentially etiologic variants.Results: We observed that potentially etiologic exonic and splice site variants were nonrandomly distributed among the nine exons ofIRF6, with 92% of these variants occurring in exons 4 and 7. Novel variants were also observed in both nonsyndromic orofacial clefts (p.Glu69Lys, p.Asn185Thr, c.175‐2A>C and c.1060+26C>T) and multiple congenital anomalies (p.Gly65Val, p.Lys320Asn and c.379+1G>T) patients. Our data also show evidence of compound heterozygotes that may modify phenotypes that emanate fromIRF6variants.Conclusions: This study demonstrates that exons 4 and 7 ofIRF6are mutational ‘hotspots’ in our cohort and thatIRF6mutants‐induced orofacial clefts may be prevalent in the Africa population, however, with variable penetrance and expressivity. These observations are relevant for detection of high‐risk families as well as genetic counseling. In conclusion, we have shown that there may be a need to combine both molecular and clinical evidence in the grouping of orofacial clefts into syndromic and nonsyndromic forms.